Carbon Reduction Plan

Supplier Name: Huma Therapeutics Limited Publication Date: 26 June 2024

Commitment to Achieving Net Zero

Huma Therapeutics Limited is committed to achieving Net Zero emissions by 2040. Our Carbon Reduction Plan delineates our current emissions data, future targets, and strategic actions to realise our environmental goals.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Our baseline emissions, calculated by an independent third party, conform to the GHG Reporting Protocol and the UK BEIS conversion factors. These calculations are based on the Financial Control emission boundary and reflect our latest emissions data.

Emissions	Total (tCO ₂ e)	GHG protocol breakdown by scope Direct Emissions from fuel combustion in own buildings and vehicles		
Scope 1	0**			
Scope 2	5*	Emissions from electricity & heating use in control of the company (Ma		
Scope 3	1,013	Emissions from the corporate value chain		
		 Purchased goods & services Capital goods Fuel-and energy-related activities Upstream transportation & distribution Waste generated in operations Business travel Employee commuting Upstream leased assets Downstream transportation & distribution Processing of sold products Use of sold products End of life treatment of sold products Downstream leased assets Franchises Investments 	501.7 36.4 41.8 0.0** 0.2 210.0 215.9 5.1 n 0.0** 0.0** 0.0** 0.0** 0.0** 0.0** 0.0** 0.0**	
Total Emissior	ns 1,018			

Baseline Year: 2022

* Our location-based scope 2 emissions for the period amounted to 39.31 tCO₂e.

** NA / Too small to warrant monitoring

Current Emissions Reporting

Emissions	Total (tCO ₂ e)	GHG protocol breakdown by scope		
Scope 1	0**	Direct Emissions from fuel combustion in own buildings and vehicles		
Scope 2	5*	Emissions from electricity & heating use in control of the company (Market-based		
Scope 3	1,013	Emissions from the corporate value chain		
		 Purchased goods & services Capital goods Fuel-and energy-related activities Upstream transportation & distribution Waste generated in operations Business travel Employee commuting Upstream leased assets Downstream transportation & distribution Processing of sold products Use of sold products End of life treatment of sold products Downstream leased assets Investments 	501.7 36.4 41.8 0.0** 0.2 210.0 215.9 5.1 0.0** 0.0** 0.0** 0.0** 0.0** 0.0** 0.0** 0.0**	

Current Reporting Year Set as Baseline Year

Total Emissions 1,018

* Our location-based scope 2 emissions for the period amounted to 39.31 tCO₂e.

** NA / Too small to warrant monitoring

Emissions Reduction Targets

- Huma Therapeutics Limited is dedicated to achieving Net Zero emissions by 2040.
- We project that our carbon emissions will decrease over the ten-year period to $590.44 \text{ tCO}_{2}e$ by 2032. Representing a 42% reduction.

Carbon Reduction Projects

- We are currently advancing towards setting a Science-Based Target through the Science-Based Target Initiative (SBTi) platform, which will help us align our goals with the latest climate science and ensure our efforts contribute meaningfully to global emissions reduction.
- We have committed to full transparency by disclosing our emissions data through the Carbon Disclosure Project (CDP), enabling us to benchmark our progress and demonstrate our commitment to environmental responsibility to our stakeholders and the wider community.

Declaration and Sign Off

This Carbon reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

26-Jun-2024 | 12:40 BST

DocuSigned by:

Mark Gilder D2C9D861F2DB4C4... Mark Gilder

Global Head of Legal Huma Therapeutics Limited